用于治疗胆管癌的futibatinib（Lytgobi）。 - Suppr | 超能文献

相似文献

1

Futibatinib (Lytgobi) for cholangiocarcinoma.用于治疗胆管癌的futibatinib（Lytgobi）。

Med Lett Drugs Ther. 2023 Apr 17;65(1674):e69-e70. doi: 10.58347/tml.2023.1674f.

2

Futibatinib (Lytgobi) for cholangiocarcinoma.用于治疗胆管癌的futibatinib（Lytgobi）。

Trends Pharmacol Sci. 2023 Mar;44(3):190-191. doi: 10.1016/j.tips.2022.12.007. Epub 2023 Jan 24.

3

Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.伏替巴替尼：为肝内胆管癌的个性化医疗铺平道路。

Future Oncol. 2023 Jun;19(17):1161-1163. doi: 10.2217/fon-2023-0318. Epub 2023 Jun 9.

4

Futibatinib: First Approval.伏替巴替尼：首次获批

Drugs. 2022 Dec;82(18):1737-1743. doi: 10.1007/s40265-022-01806-z.

5

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.伏替巴替尼：FGFR抑制剂在胆管癌领域第二次获得欧洲药品管理局批准。

ESMO Open. 2023 Dec;8(6):102049. doi: 10.1016/j.esmoop.2023.102049. Epub 2023 Nov 2.

6

Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.伴有肉瘤样变并产生粒细胞集落刺激因子的肝内胆管癌

Pathol Int. 2013 Apr;63(4):233-5. doi: 10.1111/pin.12051.

7

Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy.病例报告：经转化治疗后肝内胆管癌完全病理缓解的报告。

Front Immunol. 2022 Dec 23;13:1051130. doi: 10.3389/fimmu.2022.1051130. eCollection 2022.

8

Intrahepatic cholangiocarcinoma: a worthy challenge.肝内胆管癌：一项值得应对的挑战。

Cancer J. 2009 May-Jun;15(3):255-6. doi: 10.1097/PPO.0b013e3181a7467d.

9

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.富替替尼，一种不可逆的 FGFR1-4 抑制剂，用于治疗 FGFR 异常肿瘤。

Oncologist. 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149.

10

Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.富替比替尼：一种强效且不可逆的成纤维细胞生长因子受体抑制剂，用于治疗胆管癌。

Curr Med Chem. 2024;31(6):666-670. doi: 10.2174/0929867330666230416152913.